Treatment of latent tuberculosis infection (LTBI) is an effective way of preventing future cases of tuberculosis disease. We review pediatric and adult studies of LTBI treatment (isoniazid and rifampin monotherapy, isoniazid plus rifampin, isoniazid plus rifapentine, and rifampin plus pyrazinamide). Based upon this review and our pediatric experience, we can offer recommendations for routine (isoniazid) and alternative courses of therapy.
disease compared to 5.8% (31 of 536) of participants who received the lower dose. The study also demonstrated the efficacy of INH 5 days per week. Although duration of INH therapy was increased to 24 months, there were no additional benefits among the Alaskan Inuit over the 6-month regimens [13, 14] . Through the 1960s, researchers at the USPHS completed additional randomized controlled trials (RCTs) that collectively studied >100 000 participants including children, TB contacts, and persons with positive TSTs; most studies compared 12 months of daily INH with placebo [15] . When analysis was restricted to participants who were adherent, the protective efficacy was approximately 90%; however, substantial protection was also conferred with irregular treatment, supporting intermittent therapy. Likewise, Hsu's [16] observational studies of 2494 children who were treated with INH daily for 1 year and followed on average for 6 years, contributing to 15 943 patient years, showed greater than 99% protective efficacy given good adherence.
The International Union Against Tuberculosis and Lung Disease completed a direct comparison of 3-, 6-, and 12-month regimens of INH in 27 730 adults with TST induration >6 mm and fibrotic pulmonary lesions seen on chest radiograph [17] . During 5 years of follow-up, 1.4% of participants in the placebo group developed TB disease compared with 1.1%, 0.5%, and 0.4% in the 3-, 6-, and 12-month regimen groups, respectively. Among persons taking 80% of their INH doses, efficacy for the 12-month regimen was higher (0.1% disease progression); participants receiving the 6-month regimen had a 4-fold higher risk of TB disease than those receiving the 12-month regimen. Similar studies have not been performed in children.
Secondary analysis of INH trials including adults and children has significantly informed pediatric TB policy. Comstock [18] analyzed 2 large USPHS household contact studies to compare TB case rates among immunocompetent, adult contacts with varying durations of INH preventive therapy. His demonstration that INH efficacy plateaued at 9-10 months of treatment suggested that longer duration conferred no additional benefit. Researchers performed a systematic review of 4 USPHS and 7 non-US randomized, placebo-controlled international studies and evaluated the protective efficacy of 6-12 months of INH to prevent TB in HIV-uninfected persons (N = 73 375) [19] . They found that there was no difference in efficacy for patients treated for 12 versus 6 months. This review demonstrated a relative risk reduction of 0.40 (95% confidence interval, 0.31-0.52) and an absolute risk reduction of 0.01. Approximately 20% of the subjects were children. With these findings, it can be expected that the protective efficacy of INH should be substantially [7, [20] [21] [22] [23] [24] . At the Tuberculosis Clinic at Texas Children's Hospital, despite counseling the family and child on the importance of LTBI therapy, recommending pharmacies dispensing inexpensively priced medications, and scheduling close follow-up, the completion rate for self-supervised therapy with 9 months of INH was only 49% [24] . Adherence rates in children are not solely associated with adverse events. Extensive evidence suggests that INH is well tolerated by children and adolescents [16, 20, [25] [26] [27] . One large meta-analysis showed that the rates of jaundice and mostly mild elevation in hepatic transaminases were 0.06% and 8%, respectively [28] . Given the low frequency of hepatotoxicity, children should be monitored for symptoms of hepatotoxicity, rather than by routine laboratory evaluation. Parents and other care givers must be educated regarding potential side-effects (Table 2 ) [7, 29] . Any child in whom hepatotoxicity is suspected should immediately stop taking INH until physician evaluation and laboratory analyses can occur. Children can be monitored via history and clinical examination at monthly follow-up visits.
Recommendations. Current US and international INH guidelines recommend similar daily or twice-weekly doses but variable duration of therapy (Table 1) , with US guidelines recommending a 9-month duration and World Health Organization recommending 6-month regimens [30] . The level of protection offered by a 9-month INH regimen is 20%-30% higher than that afforded by a 6-month course [13] . Given the low rates of completion of LTBI therapy and the modest incremental benefit of 9 months versus 6 months of INH, it would not be unreasonable to accept 6 months of therapy rather than 9 months if adherence becomes an issue late in therapy. An alternative to daily therapy is twice-weekly therapy administered by direct observation, which has been shown to increase adherence when compared with self-administered therapy (96% vs 49% completion) [24] , and is safe (0.4% had elevated hepatic transaminases; none had evidence of synthetic hepatic dysfunction) and effective (only 1 child who completed treatment in the cohort of 448 children with LTBI progressed to disease) [31] . [80]
Thrombocytopenia Seen in 3.4% of patients receiving RIF for LTBI monotherapy; no other cell lineages were suppressed, was asymptomatic in almost all cases, and resolved after RIF was stopped.
[82]
Pyrazinamide Rash Estimated to occur in 2% of patients receiving RIF as part of multidrug therapy for disease.
[ 78, 80] Hepatotoxicity Abdominal pain is seen in 4%-5% of children receiving PZA as part of multidrug therapy for disease, but hepatotoxicity is rare.
[81]
Joint pain Serum uric acid increases in more than 90% of children receiving PZA, but remains within the normal range for the majority, and rarely is associated with joint pain or gout.
[81] 
Rifampin, 4 Months
There have been 3 randomized [32] [33] [34] and 8 observational studies of rifampin (RIF) for LTBI [35] [36] [37] [38] [39] [40] [41] [42] . Efficacy and Effectiveness. There have been 3 RCTs of RIF monotherapy for LTBI; all included only adults. An early study in Chinese adults with silicosis showed 3 months of RIF to be as efficacious as 6 months of INH [32] . The other 2 RCTs compared 4 months of RIF with 9 months of self-administered INH, and researchers found higher adherence rates (78%-91%) for the RIF arm compared with the INH arms (60%-76%). Subsequent studies have been largely observational [35] [36] [37] [38] [39] [40] [41] [42] . One adolescent study of RIF prospectively followed 157 high school students who were prescribed 6 months of RIF after exposure to INH-resistant M tuberculosis. No cases of active TB were identified during a 2-year study period [36] . A large scale international trial comparing 4 months of RIF with 9 months INH for the treatment of LTBI is now underway with a separate pediatric arm.
Adherence and Adverse Effects. In two randomized trials, 4 months of treatment with RIF was compared with 9 months of treatment with INH, and the results indicated significantly better treatment completion with the shorter regimen [33, 34] . A retrospective review of 2149 patients under programmatic conditions found that 72% of those who received 4 months of RIF versus 53% of those who received 9 months of INH completed treatment (P < .001), and the treatment regimen was independently associated with treatment completion [37] . Serious adverse events (Table 2) leading to discontinuation of therapy occur significantly less often with 4 months of RIF treatment compared with 9 months of INH treatment [33, 34, 37, 38] . In a large retrospective study, adverse events resulting in permanent discontinuation of medication occurred in 4.6% and 1.9% of adults in the 9 months of INH and 4 months of RIF groups, respectively [37] . The incidence of adverse reactions is not as well delineated in children. In the trial evaluating 6 months of daily RIF for the treatment of LTBI in 157 adolescents, 26% reported anorexia, nausea, fatigue, or rash, but only 1.3% required permanent discontinuation of RIF due to abdominal pain or elevation in serum transaminases [36] . Recommendations. Four months of RIF is recommended as an acceptable alternative to a 9-month regimen of INH for the treatment of adults with LTBI [1] . For children with LTBI acquired from a source with INH-resistant, RIF-susceptible M tuberculosis, the American Academy of Pediatrics recommends a 6-month regimen of RIF [30] . The difference in duration recommended for pediatric patients is due to the lack of data on the optimal treatment duration in children, but there are minimal data to support the need for a 6-month regimen. In 2 case series, including the only efficacy study that included children (one with adolescents), no patients developed TB after completing 6 months of RIF [35, 36] , compared with 1 case of disease among 1379 adults treated for 4 months with RIF in a second case series [37] .
Although the optimal duration has not been established, the results of an ongoing international trial evaluating 4 months of RIF treatment in children should provide additional information. No comparative trial of 6-month versus 4-month regimens of RIF has been conducted, but the benefits of improved adherence and safety are largely demonstrated in trials using 4 months of RIF in adults [33, 34] . Based on this, we recommend 4 months of RIF for LTBI treatment in children truly intolerant of INH or children exposed to INH-resistant, RIF-susceptible M tuberculosis. In addition, 4 months of RIF is an acceptable regimen in children infected from persons with fully drugsusceptible M tuberculosis isolates, or for children with LTBI acquired from an unknown source, given that the improved adherence demonstrated with this shorter regimen will increase the effectiveness of LTBI therapy. Of note, RIF is substantially more expensive than INH for uninsured patients who are not receiving medication via directly observed preventive therapy (DOPT).
Isoniazid + Rifampin, 3 Months
There are 9 randomized trials [32, [43] [44] [45] [46] [47] [48] [49] [50] ] and 6 observational studies [51] [52] [53] [54] [55] [56] of combination therapy with INH and RIF for LTBI. Efficacy and Effectiveness. A recent meta-analysis identified 5 high-quality RCTs comparing daily short-course treatment with INH and RIF (INH/RIF) to 6-12 months of INH [57] . The studies were conducted in Hong Kong, Spain, and Uganda, and 3 studies included patients infected with HIV. Among 1926 adults (972 treated with INH/RIF, and 954 treated with INH) who were followed for a mean of 13-37 months, the development of TB disease was equivalent for both regimens. In HIV-infected African adults with LTBI, there was no difference in death or progression to disease when 3 months of daily INH/RIF (administered via DOPT) was compared to either 6 months of INH or 3 months of INH/Rifapentine (RPT) [43] .
A study conducted exclusively among Greek children compared 4 months of INH/RIF to 9 months of INH and subsequently 4 months of INH/RIF to 3 months of INH/ RIF [44] . Some children had TB risk factors and were identified via contact investigations, whereas others were recruited based on a positive TST alone. Although the study was not adequately powered for efficacy, none of the 850 treatment-adherent patients progressed to clinical TB. The authors concluded that 3 months of INH/RIF and 4 months of INH/RIF were equivalent to each other and superior to 9 months of INH for the treatment of LTBI in children given the improved adherence.
The largest programmatic experience using 3 months of INH/RIF is from British observational studies, where 3-6 months of INH/RIF has been used to treat pediatric LTBI since 1984 [51] [52] [53] . By comparing district notifications of TB to patients treated for LTBI, Ormerod [51] demonstrated a significantly reduced incidence of childhood TB with the introduction of INH/RIF compared with historical control groups who received 9 months of INH. No additional protection was offered by a 6-month versus a 3-month regimen of INH/RIF [52] . Adherence and Adverse Effects. Adherence with 3 months of INH/RIF is generally equivalent to or better than that of longer regimens [47, 54, 55] . The rate of completion in Greek children treated for LTBI was significantly lower for 9 months of INH (66%) compared with the shorter INH/ RIF regimens (78%-90%) [44] . The adherence with 3 months of INH/RIF in high-burden settings was higher than for 6 months of INH (70% vs 28%) [55] .
Serious adverse effects, including hepatotoxicity, have occurred with similar or lower frequency with 3 months of INH/RIF compared with 6-12 months of INH [32, 43, [47] [48] [49] 57] . In the Greek pediatric study, there were no serious adverse events noted among 926 participants, and modification of treatment was not required in any patient [44] . Recommendations. Programmatic experience in England and 1 Greek study suggest that 3 months of INH/RIF therapy is as effective as 4 months [44, [51] [52] [53] . We recommend 3 months of INH/RIF based on this experience in the United Kingdom and multiple studies establishing the safety and tolerability of this regimen in children and adults [43, 44, 48, 50] .
Isoniazid and Rifapentine, 3 Months (Once-Weekly Dosing)
There have been 3 randomized trials [8, 43, 58] of combination therapy with INH and RPT.
Efficacy and Effectiveness. Rifapentine is a rifamycin with a long half-life ( 13 h) and with greater potency against M tuberculosis than RIF. It has a US Food and Drug Administration-approved indication for treating TB disease, but RPT's use for treating LTBI is off-label. Three studies were conducted to compare the use of once-weekly RPT in combination with INH given via directly observed therapy to treat LTBI [8, 43, 58] . In a small trial (206 close contacts on this regimen), 1.46% of adult subjects treated with this regimen developed TB disease compared with 0.52% of 193 subjects treated with 2 months of daily RIF and pyrazinamide (PZA) [58] . In the second study, of 328 HIV-infected adults who did not receive antiretroviral therapy and who also tested positive for TST, 24 developed TB disease, a rate of 2.0 per 100 patient years, compared with a rate of 1.9 per 100 patient years among similar patients treated for 6 months with self-administered, daily, INH [43] . The most rigorous and best designed comparative trial for treatment of LTBI was performed in a third study in Brazil, Canada, Spain, and the United States [8] . This trial compared 11 or 12 doses of INH (15-25 mg/kg, maximum 900 mg) and RPT (15 mg/kg, maximum 900 mg) given as weekly DOPT with 9 months of daily selfadministered INH (5-15 mg/kg, maximum 300 mg). The modified intention-to-treat analysis included 7731 participants with LTBI: 5466 close contacts, 1925 subjects with TST conversion, 179 subjects with radiographic findings of healed pulmonary TB, and 161 subjects who were infected with HIV and were not taking antiretroviral drugs. The completion rates of therapy were 82% and 69% for the INH and RPT and INH regimens, respectively. Of the 22 cases of TB disease observed during the average 30-month follow-up period, 7 occurred in the INH and RPT group and 15 occurred in the INH group (hazard ratio of 0.38 for the INH and RPT regimen). Initially, only persons 12 years of age were enrolled. Although younger children were enrolled later in the study after some pediatric RPT pharmacokinetic data became available [59] , there was insufficient power to determine the efficacy of treatment among children 2 to 11 years of age. Adherence and Adverse Effects. In the large comparative trial, permanent drug discontinuation was more common with the INH regimen than with INH and RPT regimen (31% vs 18%) [8] . It was obvious that adherence with the INH and RPT regimen was enhanced by the use of DOPT for all doses. Permanent discontinuation ascribed to adverse effects was more common with INH and RPT (4.9% vs 3.7%) as was discontinuation attributed to hypersensitivity reactions (2.9% vs 0.4%), but hepatotoxicity requiring discontinuation of the regimen was significantly more common with the INH regimen (2.0% vs 0.3%). In a separate analysis, 1032 children (539 received INH and RPT and 493 received INH) aged 2-17 years were enrolled in the study. For this subset, completion of the regimen was significantly higher in the INH-RPT group (88% vs 80%), and the rates of discontinuation of either regimen due to an adverse effect were very low and not different (1.3% and 0.8% for INH plus RPT and INH, respectively) [60] . There were 7 cases of possible drug hypersensitivity in the INH and RPT group compared with none in the INH group; there were no cases of significant hepatotoxicity in either group.
Recommendations. In December 2011, the Centers for Disease Control and Prevention (CDC) stated that the combination of INH and RPT given as 12 weekly DOPT doses is recommended as an equal alternative to 9 months of daily self-administered INH for treating LTBI in otherwise healthy patients aged 12 years who are at high risk for progression to TB disease. These risk factors included recent exposure to contagious TB, conversion from a negative to a positive test for TB infection, and radiographic findings of healed pulmonary TB, including HIV-infected persons who are otherwise healthy and not taking antiretroviral medications [9] . The safety and tolerability data for children aged 2-11 years were not available when these recommendations were published, but the CDC stated that INH-RPT can be considered on a case-by-case basis for children aged 2-11 years when the circumstances make completion of 9 months of INH unlikely and the likelihood or the hazard of TB is great. It is unlikely that a well powered study of the efficacy of INH-RPT will be conducted among young children aged 2-11 years. However, given the favorable results of the safety and tolerability data now available for this age group, INH-RPT should be considered an acceptable alternative when adherence with a self-administered regimen is difficult or unlikely. Because of the lack of data pertaining to the pharmacokinetics, safety, and tolerability of RPT in children <2 years of age, INH-RPT should be considered a secondary alternative to 9 months of INH.
Rifampin + Pyrazinamide, 2 Months
There have been 7 randomized [46, 48, 58, [61] [62] [63] [64] and 7 observational trials [65] [66] [67] [68] [69] [70] [71] for the use of RIF and PZA for LTBI; all were in adults.
Efficacy and Effectiveness
Studies demonstrated efficacy equivalent to 6 months of INH in HIV-infected adults [61, 63] and higher rates of completion than standard LTBI regimens [61, 66] . This regimen was never recommended for LTBI treatment in children, and it is no longer recommended for adults due to high rates of hepatotoxicity [72] . Adherence and Adverse Events. The limitations to this regimen were elevated rates of hepatotoxicity among adults: 6%-8% of 2-month RIF/PZA recipients had grade 3-4 hepatotoxicity compared with 1%-2% of 6-month INH recipients [64, 68] . Rates of hepatotoxicity may vary by population; a retrospective study of Portuguese LTBI patients who received 2 months of treatment with INH/ RIF/PZA showed comparable rates of hepatotoxicity (1.5% vs 1.6%) to those who received 6 months of treatment with INH [73] . Based on these data, the CDC recommended that 2 months of RIF/PZA may be used with caution in selected cases for the following patients: those without existing hepatic disease; those not taking other potentially hepatotoxic medications; those able to be cared for by an experienced clinician with close clinical and laboratory monitoring; and those in whom longer regimens are judged not likely to be completed [74] . Recommendations. Although it is not a recommended regimen, 2 months of RIF/PZA may be useful for children who are started on multidrug therapy for suspected TB disease (based in part upon on TST or IGRA positivity) and who are later found to have an alternative diagnosis. In these patients, receipt of at least 2 months of RIF/PZA constitutes an adequate course of LTBI therapy. Use of RIF/PZA outside this circumstance is not recommended given the risk of hepatotoxicity and availability of alternative regimens.
ADHERENCE AND MONITORING
Approximately 50% of adult Americans who start LTBI therapy do not complete it [4, 75] , and a substantial number refuse to initiate therapy; the rates are similar for children [24, 75] . Completion rates are much higher for children who receive medications via DOPT [24] . Almost half of patients who do not complete therapy discontinue it in the first 1-2 months after initiation [76] . Risk factors for initiating but not completing therapy include initiation of a 9-month course of therapy (vs shorter courses) [4] , residence in congregate settings [4] , lack of insurance [77] , and perceived side effects [77, 78] .
Poor adherence should not be surprising: many cultures do not emphasize preventive care, and because the children, by definition, are asymptomatic at initiation of LTBI therapy, parents will only notice side effects, not improvement. A child's adherence relates to numerous factors including the parents' attitude regarding preventive therapy, perceived ability to provide their child with treatment, and social norms [79] . Predicting adherence in individual patients and families is challenging. Given the frequency of nonadherence, it would be unwise for healthcare providers to assume all children receive the intended regimen. Strategies to address the most common reasons for nonadherence are listed in Table 3 . One effective strategy to increase completion rates is to offer DOPT via local health departments or in schools regularly staffed by school nurses. Although DOPT may not be available for all children in all settings, it has been shown to increase adherence in children with LTBI irrespective of socioeconomic status, immigration status, and language of preference [24] .
Children who receive LTBI therapy require frequent monitoring to assess adherence, address family concerns, and assess for potential side effects (Tables 2 and 4 ) [80] [81] [82] . For the otherwise healthy child who only receives TB medication(s), baseline and serial laboratory evaluation is unnecessary. Results of studies have shown that 3% of children who receive TB medications have asymptomatic elevation in transaminases 2-3 times the upper limit of normal (ULN) [83] ; in these cases, modification of therapy is not needed. Elevations >3 times ULN with accompanying symptoms or >5 times ULN without symptoms define hepatotoxicity. Hepatotoxicity may range from isolated transaminitis to hyperbilirubinemia to hepatic failure. If children are receiving other potentially hepatotoxic medications or have known or suspected hepatic dysfunction, measurement of baseline hepatic transaminases may be warranted. Obtaining transaminase concentrations is also warranted for the child who develops abdominal complaints, anorexia, or malaise while taking TB medication. Most children who receive TB medications with abdominal complaints have normal laboratory evaluation. Even in children with transaminitis, many cases will be due to viral infections rather than medication toxicity.
CONCLUSIONS
The decision to initiate therapy for LTBI in children is made easier by the very favorable risk/benefit ratio compared with adults: risks are minimized because children tolerate TB medications better than adults, and children benefit more because they have increased risk of progression to disease. Six treatment regimens for LTBI have been demonstrated to have efficacy based mainly on studies in adults, but only the effectiveness of INH alone has been studied extensively in children. For TB disease, drug regimens that have been shown to be effective in adults have been at least equally effective in children, and it is likely that the same would be true of regimens to treat LTBI. It is unlikely that large clinical trials of the newer regimens adequately powered to determine efficacy will be conducted in children because of cost. However, the safety and tolerability of additional or alternative drugs and regimens can be established with smaller numbers of children. There are ample data to confirm that RIF for all ages of children and RPT for children 2 years of age are safe and well tolerated by the large majority of children.
The American Academy of Pediatrics and the CDC currently recommend 9 months of INH as preferred therapy for children. However, there is increasing concern that the effectiveness of this regimen in clinical practice is far less than the efficacy demonstrated in clinical trials because the estimated completion rate for 9 months of selfadministered INH often is less than 50%. Shorter Please warn families about orange urinary (and occasionally, tears and sweat) discoloration with rifampin, and warn adolescent females that rifampin, among its many drug interactions, inactivates oral contraceptives. Other drug interactions include HIV protease inhibitors, non-nucleoside reverse-transcriptase inhibitors, corticosteroids, and phenytoin.
regimens with single or multiple drugs should result in higher rates of adherence. Therefore, it is reasonable to consider shorter regimens for children when a 9-month regimen of INH is unlikely to be completed. Regimen selection must balance efficacy (degree of protection described in trials) with the rates and types of adverse events (low in children for all the described regimens), adherence, and (if available) drug susceptibilities for the isolate obtained from the person with TB disease who has been in contact with the child. The increasing incidence of drug shortages also supports the wisdom of having several regimens. A highly efficacious regimen may have limited effectiveness in routine clinical use if a substantial number of patients do not complete the regimen. For children 12 years and older, the best alternative to 9 months of INH therapy for LTBI may be 12 weekly doses of INH + RPT administered by DOPT. This regimen is short, effective, well tolerated, and has the advantage of the fewest number of doses. Unfortunately, it is not currently recommended to give this regimen as self-administered treatment. Rifapentine has been in short supply, so many health departments have not yet been able to scale-up widespread use of this regimen. The next best alternative to 9 months of INH alone is 4 months of RIF (to optimize adherence). Acceptable but less well studied regimens are 3 months of daily INH + RIF or 6 months of INH. A regimen of 2 months of RIF + PZA should be considered acceptable only for children with TB LTBI in whom TB disease was suspected initially and who were treated with INH, RIF, PZA, and ethambutol therapy for 2 months.
Historically, there has been a single recommended regimen for the treatment of LTBI for all children. However, numerous studies and programs have demonstrated that this monolithic approach is not sufficient to meet the needs and abilities of all patients and families. There are several safe, available regimens that can be used to serve the needs of both patients and providers in the various clinical and epidemiologic circumstances in which LTBI is identified and managed.
